person · Reporting owner

KOZIN MARC D

Disclosed activity across 8 companies

Tapewire entity: 19195
SEC CIK: 0001241647

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Decoy Therapeutics Inc.FLKS · Entity 937	Director	July 25, 2018	July 26, 2018
Notable Labs, Ltd.VBLT · Entity 87239	Director	January 01, 2023	January 04, 2023
UFP TECHNOLOGIES INCUFPT · Entity 4409	Director	August 25, 2026	August 27, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Decoy Therapeutics Inc.

Report date July 25, 2018 · Filed July 26, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-07-25	Direct	10,000	Reported balance After 2018-07-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-07-25 · Grant · Acquired 10,000 · Balance 10,000 F1: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018.

Notable Labs, Ltd.

Report date January 01, 2023 · Filed January 04, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy Marc D. Kozin Irrevocable Trust	39,000	Reported balance Holding disclosure · report date 2023-01-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 39,000 F1: These shares are held by the Marc D. Kozin Irrevocable Trust, of which the Reporting Person's spouse is one of the beneficiaries. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.30 · Expires 2036-05-05	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: These options were granted on 05/05/16 under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.17 · Expires 2040-11-24	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · Balance Not disclosed F3: These options were granted on 11/24/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on November 24, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.38 · Expires 2041-07-20	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · Balance Not disclosed F4: These options were granted on 07/20/21 under the 2014 Plan, with 25% of the shares underlying these options vesting on July 20, 2022 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.31 · Expires 2041-12-07	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · Balance Not disclosed F5: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.12 · Expires 2042-01-02	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-01-01 · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · Balance Not disclosed F6: These options were granted on 01/02/22 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are held by the Marc D. Kozin Irrevocable Trust, of which the Reporting Person's spouse is one of the beneficiaries. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, if any.

F2: These options were granted on 05/05/16 under the Issuer's Employee Share Ownership and Option Plan (2014) (the "2014 Plan") and are fully vested and exercisable.

F3: These options were granted on 11/24/20 under the 2014 Plan, with 25% of the shares underlying these options vesting on November 24, 2021 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.

F4: These options were granted on 07/20/21 under the 2014 Plan, with 25% of the shares underlying these options vesting on July 20, 2022 (the one year anniversary of the grant date), and the remainder vesting quarterly thereafter for three years such that they are vested in full on the four-year anniversary of the grant date.

F5: These options were granted on 12/07/21 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

F6: These options were granted on 01/02/22 under the 2014 Plan and vest over two years commencing on the grant date such that 50% vest on the first anniversary of the date of grant and the remainder vest quarterly thereafter for one year such that they are vested in full on the two-year anniversary of the grant date.

UFP TECHNOLOGIES INC

Report date August 25, 2026 · Filed August 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, $.01 Par ValueSEC Table I · non-derivative	Direct	21,112	Ending reported balance After 2026-08-25 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-08-25 · Sale · Disposed 3,650 · Balance 24,462 F1: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $303.58 to $304.49, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Row 2 · 2026-08-25 · Sale · Disposed 3,350 · Balance 21,112 F2: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $304.64 to $305.41, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Filing footnotes · ownership attribution and instrument terms

F1: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $303.58 to $304.49, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

F2: The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $304.64 to $305.41, inclusive. The reporting person undertakes to provide UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Past disclosures · reporting ended (5)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CHIMERIX INC

Report date April 21, 2025 · Filed April 21, 2025

Section 16 reporting ended · disclosed 2025-04-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.99 · Expires 2034-03-19	Direct	0	Reported balance After 2025-04-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2025-04-21 · Disposition to issuer · Disposed 100,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2034-06-19	Direct	0	Reported balance After 2025-04-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-04-21 · Disposition to issuer · Disposed 60,000 · Balance 0 F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting). F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2] F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 4, 2025, by and among Chimerix, Inc. ("Chimerix"), Jazz Pharmaceuticals Public Limited Company ("Parent") and Pinetree Acquisition Sub, Inc., an indirect wholly owned subsidiary of Parent ("Purchaser"). Pursuant to the Merger Agreement, Parent and Purchaser launched a tender offer (the "Offer") for all outstanding shares of common stock of Chimerix (each, a "Share") for an offer price of $8.55 per Share in cash (the "Offer Price"), without interest and subject to reduction for any applicable withholding taxes. The Offer expired at the end of the day, one minute after 11:59 p.m. Eastern Time on April 17, 2025. [continues to Footnote 2]

F2: [continues from Footnote 1] On April 21, 2025, following the filing of the certificate of merger with the Secretary of State of the State of Delaware (the "Effective Time"), Purchaser merged with and into Chimerix, with Chimerix continuing as a surviving corporation and an indirect wholly owned subsidiary of Parent (the "Merger"). At the Effective Time, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price, without any interest and subject to any withholding of applicable taxes.

F3: Pursuant to the Merger Agreement, each option to purchase Shares (each, an "Option") that was outstanding and unexercised as of immediately prior to the Effective Time, which has a per share exercise price that is less than the Offer Price (an "In the Money Option"), to the extent unvested, was accelerated and became fully vested and exercisable. Each outstanding and unexercised vested option (after giving effect to the acceleration treatment set forth in the preceding sentence) at the Effective Time was cancelled and converted into the right to receive a cash payment equal to (i) the excess of (A) the Offer Price over (B) the exercise price payable per Share of such In the Money Option, multiplied by (ii) the total number of Shares subject to such In the Money Option immediately prior to the Effective Time (without regard to vesting).

Dicerna Pharmaceuticals Inc

Report date December 28, 2021 · Filed December 29, 2021

Section 16 reporting ended · disclosed 2021-12-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2021-12-28 transaction · row 1 1 source row Row 1 · 2021-12-28 · Disposition to issuer · Disposed 6,333 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Common StockSEC Table I · non-derivative	IndirectBy Marc D. Kozin Revocable Trust	Reported balance After 2021-12-28 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-12-28 · Disposition to issuer · Disposed 5,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2021-12-28 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-12-28 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.31	Direct	Reported balance After 2021-12-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.44	Direct	Reported balance After 2021-12-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.61	Direct	Reported balance After 2021-12-28 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.47	Direct	Reported balance After 2021-12-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share, including the Reporting Person's Shares, was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.

F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.

F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).

F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).

ENDOCYTE INC

Report date December 21, 2018 · Filed December 21, 2018

Section 16 reporting ended · disclosed 2018-12-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 1 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 1 · 2018-12-21 · Disposition to issuer · Disposed 7,800 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-12-21 transaction · row 2 Sequence does not reconcile; account continuity is unresolved. 1 source row Row 2 · 2018-12-21 · Disposition to issuer · Disposed 3,300 · Balance 0 F2: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.71 · Expires 2022-07-25	Direct	Reported balance After 2018-12-21 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-12-21 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.94 · Expires 2023-06-19	Direct	Reported balance After 2018-12-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-12-21 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.69 · Expires 2024-05-15	Direct	Reported balance After 2018-12-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-12-21 · Disposition to issuer · Disposed 14,000 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.02 · Expires 2025-05-14	Direct	Reported balance After 2018-12-21 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2018-12-21 · Disposition to issuer · Disposed 13,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2026-05-05	Direct	Reported balance After 2018-12-21 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-12-21 · Disposition to issuer · Disposed 13,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.27 · Expires 2027-05-04	Direct	Reported balance After 2018-12-21 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0 F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.81 · Expires 2028-05-03	Direct	Reported balance After 2018-12-21 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-12-21 · Disposition to issuer · Disposed 19,500 · Balance 0 F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes.

F2: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes.

F3: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

F4: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes.

Isleworth Healthcare Acquisition Corp.

Report date September 08, 2021 · Filed September 10, 2021

Section 16 reporting ended · disclosed 2021-09-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-09-08 transaction · row 1 1 source row Row 1 · 2021-09-08 · Other · Disposed 36,000 · Balance 0 F1: In connection with the resignation of the reporting person from the Issuer's board of directors, the reporting person transferred for no consideration 36,000 shares of Issuer common stock to the new director of the Issuer filling the vacancy left by the reporting person's resignation.

Filing footnotes · ownership attribution and instrument terms

F1: In connection with the resignation of the reporting person from the Issuer's board of directors, the reporting person transferred for no consideration 36,000 shares of Issuer common stock to the new director of the Issuer filling the vacancy left by the reporting person's resignation.

Tempest Therapeutics, Inc.

Report date December 07, 2018 · Filed December 12, 2018

Section 16 reporting ended · disclosed 2018-12-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,740	Reported balance After 2018-12-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2018-12-07 · Grant · Acquired 831 · Balance 7,740 F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $5,000 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $5,000 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan.

F2: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to Buy) · Derivative	1,227	$0.00 Strike: $19.08	$0.00	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · derivative · entry 11 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock, $.01 Par Value · 1,227 shares Expires 2023-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Righto toBuy) · Derivative	1,295	$0.00 Strike: $16.32	$0.00	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · derivative · entry 10 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock, $.01 Par Value · 1,295 shares Expires 2022-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to Buy) · Derivative	2,058	$0.00 Strike: $16.17	$0.00	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · derivative · entry 9 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock, $.01 Par Value · 2,058 shares Expires 2021-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	1,724	$31.20	$53,788.80	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · nonDerivative · entry 8 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	2,056	$27.05	$55,614.80	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · nonDerivative · entry 7 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	2,864	$22.02	$63,065.28	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · nonDerivative · entry 6 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	2,921	$19.97	$58,332.37	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · nonDerivative · entry 5 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	2,088	$25.04	$52,283.52	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · nonDerivative · entry 4 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,972 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	1,227	$19.08	$23,411.16	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · nonDerivative · entry 3 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,884 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	1,295	$16.32	$21,134.40	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · nonDerivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 06, 2020 Filed Mar 10, 2020 13:24 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	2,058	$16.17	$33,277.86	Disclosure SEC source: 0001240679-20-000042 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 11, 2019 Filed Sep 12, 2019 19:37 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	455	$40.05	$18,222.75	Disclosure SEC source: 0001373894-19-000067 · edgar.xml · nonDerivative · entry 4 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,304 F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.00 to $40.44, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
September 11, 2019 Filed Sep 12, 2019 19:37 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	3,342	$39.90	$133,345.80	Disclosure SEC source: 0001373894-19-000067 · edgar.xml · nonDerivative · entry 3 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,759 F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.42 to $39.99, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
September 10, 2019 Filed Sep 12, 2019 19:37 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	1,075	$40.53	$43,569.75	Disclosure SEC source: 0001373894-19-000067 · edgar.xml · nonDerivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,101 F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.14 to $40.70, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
September 10, 2019 Filed Sep 12, 2019 19:37 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	SaleCommon Stock, $.01 Par Value	1,535	$39.50	$60,632.50	Disclosure SEC source: 0001373894-19-000067 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,176 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $39.37 to $39.86, inclusive. The reporting person undertakes to provide to UFP Technologies, Inc., any security holder of UFP Technologies, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. Read SEC document
September 05, 2019 Filed Sep 9, 2019 15:08 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to buy) · Derivative	3,500	$0.00 Strike: $9.25	$0.00	Disclosure SEC source: 0001373894-19-000065 · edgar.xml · derivative · entry 4 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 3,500 shares Expires 2020-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 05, 2019 Filed Sep 9, 2019 15:08 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to Buy) · Derivative	2,907	$0.00 Strike: $9.09	$0.00	Disclosure SEC source: 0001373894-19-000065 · edgar.xml · derivative · entry 3 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 2,907 shares Expires 2020-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 05, 2019 Filed Sep 9, 2019 15:08 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	3,500	$9.25	$32,375.00	Disclosure SEC source: 0001373894-19-000065 · edgar.xml · nonDerivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,711 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 05, 2019 Filed Sep 9, 2019 15:08 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	2,907	$9.09	$26,424.63	Disclosure SEC source: 0001373894-19-000065 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 20, 2019 Filed Jun 22, 2019 00:03 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	GrantDirector Stock Option (right to buy) · Derivative	25,000	$0.00 Strike: $15.44	$0.00	Disclosure SEC source: 0000899243-19-017866 · doc4.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: This option vests monthly over 12 months from June 20, 2019 ("Grant Date") in substantially equal monthly installments, provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such date or, if earlier, such annual meeting. Read SEC document
June 05, 2019 Filed Jun 7, 2019 20:32 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantStock Option (Right to Buy) · Derivative	2,756	$0.00 Strike: $38.61	$0.00	Disclosure SEC source: 0001373894-19-000054 · edgar.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,756 Underlying: Common Stock, $.01 Par Value · 2,756 shares Expires 2029-06-05 Read SEC document
June 05, 2019 Filed Jun 7, 2019 20:32 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantCommon Stock, $.01 Par Value	907	$0.00	$0.00	Disclosure SEC source: 0001373894-19-000054 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,304 F1 · shares: Represents restricted stock units issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan that are to be settled solely in shares of Common Stock. The units vest with respect to 100% of the shares on May 31, 2020, so long as the recipient continues as a director of the Issuer through the vesting date. Read SEC document
January 23, 2019 Filed Jan 26, 2019 02:10 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	GrantDirector Stock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $10.31	$0.00	Disclosure SEC source: 0000899243-19-001994 · doc4.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-23 F1 · derivative.exercise_date: This option vests as to one-third of the underlying shares on the one year anniversary of the date of grant and as to the remaining two-thirds of the shares in quarterly installments over the two-year period thereafter, subject in each case to the Reporting Person's continued service through the applicable vesting date. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:48 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	19,500	$13.19 Strike: $10.81	$257,205.00	Disclosure SEC source: 0001104659-18-074341 · a4.xml · derivative · entry 9 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,500 shares Expires 2028-05-03 F4 · price: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F4 · derivative.exercise_date: This Company stock option was scheduled to vest 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:48 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	19,500	$21.73 Strike: $2.27	$423,735.00	Disclosure SEC source: 0001104659-18-074341 · a4.xml · derivative · entry 8 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,500 shares Expires 2027-05-04 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:48 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	13,500	$20.65 Strike: $3.35	$278,775.00	Disclosure SEC source: 0001104659-18-074341 · a4.xml · derivative · entry 7 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,500 shares Expires 2026-05-05 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:48 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	13,500	$17.98 Strike: $6.02	$242,730.00	Disclosure SEC source: 0001104659-18-074341 · a4.xml · derivative · entry 6 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,500 shares Expires 2025-05-14 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:48 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	14,000	$17.31 Strike: $6.69	$242,340.00	Disclosure SEC source: 0001104659-18-074341 · a4.xml · derivative · entry 5 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2024-05-15 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:48 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	14,000	$11.06 Strike: $12.94	$154,840.00	Disclosure SEC source: 0001104659-18-074341 · a4.xml · derivative · entry 4 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,000 shares Expires 2023-06-19 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:48 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerStock Option (right to buy) · Derivative	20,000	$16.29 Strike: $7.71	$325,800.00	Disclosure SEC source: 0001104659-18-074341 · a4.xml · derivative · entry 3 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-07-25 F3 · price: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. F3 · derivative.exercise_date: This Company stock option was fully vested immediately prior to the Effective Time. Pursuant to the Merger Agreement, at the Effective Time, each Company stock option that was outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to the excess of $24.00 over the exercise price with respect to such stock option, multiplied by the number of shares of Company common stock subject to such stock option, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:48 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerCommon Stock	3,300	$24.00	$79,200.00	Disclosure SEC source: 0001104659-18-074341 · a4.xml · nonDerivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: This restricted stock unit ("RSU") award provided for vesting and settlement 100% on the business day prior to the Company's annual stockholder meeting following May 3, 2018 in the form of one share of Company common stock for each RSU. Pursuant to the Merger Agreement, at the Effective Time, each RSU outstanding immediately prior to the Effective Time was canceled and converted into the right to receive an amount in cash, without interest, equal to $24.00, multiplied by the number of shares of Company common stock subject to such RSU, less any applicable withholding taxes. Read SEC document
December 21, 2018 Filed Dec 21, 2018 17:48 UTC	ENDOCYTE INC ECYT · Entity 161591	Disposition to issuerCommon Stock	7,800	$24.00	$187,200.00	Disclosure SEC source: 0001104659-18-074341 · a4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated as of October 17, 2018 (the "Merger Agreement"), by and among Endocyte, Inc. (the "Company"), Novartis AG ("Novartis") and Edinburgh Merger Corporation, a wholly owned subsidiary of Novartis ("Merger Sub"), at the effective time (the "Effective Time") of the merger of Merger Sub with and into the Company, which Effective Time occurred on December 21, 2018, each share of Company common stock was converted into the right to receive an amount in cash equal to $24.00, without interest and less any applicable withholding taxes. Read SEC document
December 07, 2018 Filed Dec 12, 2018 00:42 UTC	Tempest Therapeutics, Inc. MLND · Entity 7734	GrantCommon Stock	831	$0.00	$0.00	Disclosure SEC source: 0001209191-18-062119 · doc4.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,740 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $5,000 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. F2 · shares: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. F1 · price: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $5,000 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. F2 · balance_after: Reflects the reverse stock split of Millendo common stock, effective as of December 7, 2018. Read SEC document
September 28, 2018 Filed Oct 2, 2018 22:03 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	16,014	$0.00	$0.00	Disclosure SEC source: 0001179110-18-011956 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,647 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $11,687.50 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. F1 · price: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $11,687.50 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document
July 25, 2018 Filed Jul 26, 2018 20:04 UTC	Decoy Therapeutics Inc. FLKS · Entity 937	GrantStock Option (right to buy) · Derivative	10,000	$0.00 Strike: $0.82	$0.00	Disclosure SEC source: 0001615219-18-000046 · wf-form4_153263542891597.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-07-25 F1 · derivative.exercise_date: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018. Read SEC document
July 04, 2018 Filed Jul 6, 2018 22:34 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $0.95	$0.00	Disclosure SEC source: 0001179110-18-009536 · edgar.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-07-04 F1 · derivative.exercise_date: The stock option will vest in twelve equal monthly installments at the end of each successive month following July 4, 2018. Read SEC document
June 29, 2018 Filed Jul 3, 2018 20:38 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	12,880	$0.00	$0.00	Disclosure SEC source: 0001179110-18-009350 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,633 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $11,687.50 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. F1 · price: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $11,687.50 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document
June 06, 2018 Filed Jun 7, 2018 20:23 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantStock Option (Right to Buy) · Derivative	1,724	$0.00 Strike: $31.20	$0.00	Disclosure SEC source: 0001739481-18-000028 · edgar.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,724 Underlying: Common Stock, $.01 Par Value · 1,724 shares Expires 2028-06-06 Read SEC document
June 06, 2018 Filed Jun 7, 2018 20:23 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	GrantCommon Stock, $.01 Par Value	561	$0.00	$0.00	Disclosure SEC source: 0001739481-18-000028 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,397 F1 · shares: Represents shares issued under the issuer's 2009 Non-Employee Director Stock Incentive Plan Read SEC document
May 14, 2018 Filed May 16, 2018 19:56 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (right to buy) · Derivative	4,500	$0.00 Strike: $10.14	$0.00	Disclosure SEC source: 0001739481-18-000024 · edgar.xml · derivative · entry 4 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 4,500 shares Expires 2018-06-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2018 Filed May 16, 2018 19:56 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionStock Option (Right to Buy) · Derivative	2,615	$0.00 Strike: $12.37	$0.00	Disclosure SEC source: 0001739481-18-000024 · edgar.xml · derivative · entry 3 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, $.01 Par Value · 2,615 shares Expires 2018-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2018 Filed May 16, 2018 19:56 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	4,500	$10.14	$45,630.00	Disclosure SEC source: 0001739481-18-000024 · edgar.xml · nonDerivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,836 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 14, 2018 Filed May 16, 2018 19:56 UTC	UFP TECHNOLOGIES INC UFPT · Entity 4409	Exercise / conversionCommon Stock, $.01 Par Value	2,615	$12.37	$32,347.55	Disclosure SEC source: 0001739481-18-000024 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,336 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 03, 2018 Filed May 4, 2018 21:07 UTC	ENDOCYTE INC ECYT · Entity 161591	GrantStock Option (right to buy) · Derivative	19,500	$0.00 Strike: $10.81	$0.00	Disclosure SEC source: 0001179110-18-006322 · edgar.xml · derivative · entry 2 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,500 Underlying: Common Stock · 19,500 shares Expires 2028-05-03 F2 · derivative.exercise_date: 100% of options vest on the business day prior to the next annual stockholder meeting following the date of grant. Read SEC document
May 03, 2018 Filed May 4, 2018 21:07 UTC	ENDOCYTE INC ECYT · Entity 161591	GrantCommon Stock	3,300	$0.00	$0.00	Disclosure SEC source: 0001179110-18-006322 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,100 F1 · shares: Represents restricted stock units that will vest 100% on the business day prior to the next annual stockholder meeting following the date of grant, and will be paid in the form of one share of common stock for each restricted stock unit. Read SEC document
March 30, 2018 Filed Apr 3, 2018 21:26 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	14,411	$0.00	$0.00	Disclosure SEC source: 0001179110-18-005303 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,753 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $11,687.50 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. F1 · price: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $11,687.50 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document
December 29, 2017 Filed Jan 4, 2018 01:42 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	8,348	$0.00	$0.00	Disclosure SEC source: 0001179110-18-000450 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,342 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $11,687.50 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. F1 · price: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of $11,687.50 of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document
September 29, 2017 Filed Oct 3, 2017 23:47 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	8,230	$0.00	$0.00	Disclosure SEC source: 0001179110-17-013053 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,994 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document
July 26, 2017 Filed Jul 27, 2017 12:51 UTC	Decoy Therapeutics Inc. FLKS · Entity 937	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $4.08	$0.00	Disclosure SEC source: 0001615219-17-000051 · wf-form4_150115985633013.xml · derivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-07-26 F1 · derivative.exercise_date: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017. Read SEC document
June 30, 2017 Filed Jul 5, 2017 23:11 UTC	Tempest Therapeutics, Inc. OVAS · Entity 7734	GrantCommon Stock	6,477	$0.00	$0.00	Disclosure SEC source: 0001179110-17-010099 · edgar.xml · nonDerivative · entry 1 KOZIN MARC D · CIK 0001241647 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,764 F1 · kind: The shares reported on this Form 4 were issued to the Reporting Person, who elected to take shares in lieu of cash compensation for services as a director and committee member, pursuant to the Issuer's non-employee director compensation plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.